Tempus AI is trading 4.18% down at $64.79 on October 26, 2026; no verified report has identified a specific catalyst.
- Before the market opened, the company announced EU IVDR certification for its xR assay. Analyst coverage included reiterated Buy ratings; neither development was linked to the decline.
- The provided major indices were modestly higher, so broad-market weakness does not explain the move.
- The October 23 Bristol Myers Squibb and Pathos agreements were prior-session news, not a confirmed explanation for Monday’s decline.